Recruiting NCT07416682

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Early Phase I Interventional High-risk Plasma Cell Neoplasms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: CAR BCMA-CD70-T cells, fludarabine and cyclophosphamide.
Who it may be relevant to: Registry conditions: High-risk Plasma Cell Neoplasms. Basic parameters: 18 years — 75 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: China
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Official title

Clinical Study on the Safety and Efficacy of CAR BCMA-CD70 Dual-target CAR-T Therapy for High-risk Plasma Cell Neoplasms

This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.

Genetic CAR BCMA-CD70-T cells
Each subject will be infused with single dose of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.
Drug fludarabine and cyclophosphamide
Description: Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of BCMA-CD70-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of BCMA-CD70-CAR-T cells.

According to the incidence of treatment-related adverse events (AEs) to evaluate the safetyof CAR BCMA-CD70 CAR-T cells in the treatment of CD70/BCMA positive high-risk plasma cell neoplasms. [Time frame: up to 3 years]
According to the determine the Maximal Tolerable Dose(MTD) to evaluate the safety of CAR BCMA-CD70 CAR-T cells in the treatment of CD70/BCMA positive high-risk plasma cell neoplasms. [Time frame: MTD will be determined based on DLTs observed during the first 28 days of study treatment]

Secondary outcome measures (1)

According to the objective response rate (ORR) to evaluate the efficacy of CAR BCMA-CD70 CAR-T cells in the treatment of CD70/BCMA positive high-risk plasma cell neoplasms. [Time frame: Within 3 months following infusion of CAR BCMA-CD70 CAR-T cells]

The subject or their legally acceptable representative has provided written informed consent and is willing and able to comply with all scheduled study visits, study treatment administration, laboratory tests, and other required trial procedures.
Clinically diagnosed with high-risk plasma cell neoplasm, meeting any one of the following molecular/cytogenetic or clinical criteria:

Deletion of the short arm of chromosome 17 (del(17p)) with clonal proportion ≥ 20%, and/or TP53 gene mutation;
IgH translocation (t(4;14), t(14;16), or t(14;20)) combined with 1q amplification (1q+) and/or deletion of the short arm of chromosome 1 (del(1p32));
Chromosome 1 abnormalities: monoallelic del(1p32) plus 1q+, or biallelic del(1p32);
β₂-microglobulin ≥ 5.5 mg/L with normal serum creatinine (< 1.2 mg/dL).
Age 18 to 75 years (inclusive), male or female.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Life expectancy > 3 months from the date of signed informed consent.
Hemoglobin (HGB) ≥ 60 g/L (transfusion permitted).
Adequate hepatic, renal, and cardiopulmonary function as defined by:

Serum creatinine ≤ 2 × ULN;
Left ventricular ejection fraction (LVEF%) ≥ 50%;
Blood oxygen saturation > 90%;
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN.
Subject agrees to use highly effective contraception from the date of informed consent until 1 year after CAR-T cell infusion.

Severe cardiac insufficiency with left ventricular ejection fraction (LVEF%) < 50%.
History of severe chronic lung disease associated with impaired pulmonary function.
Concurrent active or progressive malignant tumors other than the target plasma cell neoplasm.
Concurrent severe infection that cannot be effectively controlled with standard therapy.
Concurrent severe autoimmune disease or congenital immunodeficiency disorders.
Active viral hepatitis, defined as hepatitis B virus DNA (HBV-DNA) or hepatitis C virus RNA (HCV-RNA) levels above the lower limit of detection (LLOD).
Human immunodeficiency virus (HIV) infection, known acquired immunodeficiency syndrome (AIDS), or syphilis infection.
History of severe allergic reactions to biological products, including antibiotics.
Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with persistent acute graft-versus-host disease (aGVHD) that does not resolve within 1 month after discontinuing immunosuppressive therapy.
Presence of other severe physical or psychiatric illnesses, or significant laboratory abnormalities, that may increase the risks of study participation, interfere with study outcomes, or render the subject otherwise unsuitable for enrollment as determined by the investigator.
Female subjects of childbearing potential who are pregnant or breastfeeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

China · 1 center

the Fifth Medical Center of Chinese People's Liberation Army General Hospital — Beijing

NCT: NCT07416682 · CAR BCMA-70-XYBYXB